BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29085997)

  • 1. CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer.
    Wei Y; Lin C; Li H; Xu Z; Wang J; Li R; Liu H; Zhang H; He H; Xu J
    Cancer Immunol Immunother; 2018 Feb; 67(2):261-269. PubMed ID: 29085997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
    Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
    Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
    Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
    Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Jung HH; Kim JY; Cho EY; Lee JE; Kim SW; Nam SJ; Park YH; Ahn JS; Im YH
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum CXCL13 and PECAM-1 can be used as diagnostic and prognostic markers in elderly patients with gastric cancer.
    Li Y; Guo XB; Wei YH; Kang XL
    Clin Transl Oncol; 2021 Jan; 23(1):130-138. PubMed ID: 32500259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.
    Cao Y; Liu H; Li H; Lin C; Li R; Wu S; Zhang H; He H; Zhang W; Xu J
    JAMA Surg; 2017 Nov; 152(11):e173120. PubMed ID: 28903131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 10. The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.
    Wang Z; Liu H; Shen Z; Wang X; Zhang H; Qin J; Xu J; Sun Y; Qin X
    BMC Cancer; 2015 Oct; 15():766. PubMed ID: 26497045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.
    Bamias A; Karina M; Papakostas P; Kostopoulos I; Bobos M; Vourli G; Samantas E; Christodoulou Ch; Pentheroudakis G; Pectasides D; Dimopoulos MA; Fountzilas G
    Cancer Chemother Pharmacol; 2010 May; 65(6):1009-21. PubMed ID: 20130877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of the tumor deposit in N0 gastric cancer by propensity score matching analysis].
    Zhi C; Yang W; Li N; Zhang Z; Hua Y; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):172-179. PubMed ID: 30799540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis.
    Lin JX; Wang ZK; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Huang CM; Li P
    Cancer Commun (Lond); 2019 Feb; 39(1):4. PubMed ID: 30744696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.
    Maezawa Y; Sakamaki K; Oue N; Kimura Y; Hashimoto I; Hara K; Kano K; Aoyama T; Hiroshima Y; Yamada T; Yamamoto N; Ogata T; Ito H; Cho H; Shiozawa M; Yoshikawa T; Morinaga S; Rino Y; Yasui W; Masuda M; Miyagi Y; Oshima T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):75-86. PubMed ID: 31754833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
    He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
    World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
    Kim JW; Cho HJ; Kim M; Lee KH; Kim MA; Han SW; Oh DY; Lee HJ; Im SA; Kim TY; Yang HK; Kim WH; Bang YJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1435-43. PubMed ID: 23633032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
    Wakatsuki T; Yamamoto N; Sano T; Chin K; Kawachi H; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Matsushima T; Suenaga M; Shinozaki E; Hiki N; Ishikawa Y; Yamaguchi K
    J Gastroenterol; 2018 Nov; 53(11):1186-1195. PubMed ID: 29633013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
    Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
    Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.
    Zhang H; Liu H; Shen Z; Lin C; Wang X; Qin J; Qin X; Xu J; Sun Y
    Ann Surg; 2018 Feb; 267(2):311-318. PubMed ID: 27763900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
    Chen Y; Xia X; Wang S; Wu X; Zhang J; Zhou Y; Tan Y; He S; Qiang F; Li A; Røe OD; Zhou J
    J Gastroenterol; 2013 Sep; 48(9):1034-44. PubMed ID: 23307041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.